Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Carcinoma

Urinary Bladder Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

Bladder Cancer (BCa) is the 9th most common cancer worldwide. In general, BCa is presented as a non-muscle invasive bladder cancer (NMIBC) in 70% of patients and treated with transurethral resection of bladder tumor (TUR-BT). However, in cases of muscle invasive bladder cancer (MIBC), radical cystectomy (RC) is the gold standard of treatment. Therefore, It is important to distinguish MIBC from NMIBC.

To date, pathologic staging is based on the result of TUR-BT before RC. However, it is operator dependent, thus residual cancer may be remained depending on surgical experience. Therefore, about 7%-30% patients of MIBC can be underestimated with NMIBC, and it can be increased to 45% if the muscle is not resected. Consequently, it has been raised the need for imaging test to overcome diagnostic limitations.

Multiparametric magnetic resonance imaging (mpMRI) has been widely used in the field of diagnosis of BCa. In 2018, the Vesical Imaging Report and Data System (VI-RADS) was published using T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and dynamic contrast enhanced (DCE) imaging, and 5-point VI-RADS scoring system has been proposed and reported as an imaging test useful for assessing muscle involvement in primary bladder cancer Therefore, in this study, we investigate the diagnostic performance of the VI-RADS scoring system that can differentiate NMIBC from MIBC in primary bladder cancer.

Clinical Utility of VI-RADS in Diagnosis of MIBC

Clinical Utility of Vesical Imaging Report and Data System (VI-RADS) in Diagnosis of Muscle Invasive Bladder Cancer

diagnostic accuracy of VI-RADS scoring system in diagnosis of MIBC

clinical utility of VI-RADS to predict MIBC after repeat TUR-BT in high risk NMIBC (To predict the chance of MIBC after repeat TUR-BC according to VI-RADS score in patients with high risk MNIBC)

clinical utility of VI-RADS to reduce unnecessary repeat TUR-BT in high risk NMIBC (To predict the chance of NMIBC after repeat TUR-BC according to VI-RADS score in patients with high risk MNIBC)

Prediction of MIBC according to the VI-RADS scoring system

Study title	NCT ID	Conditions	Eligibility	Organization
Clinical Utility of VI-RADS in Diagnosis of MIBC	NCT05097404	Radical Cystect... Muscle-Invasive... Multiparametric... Vesical Imaging...	18 Years -	Samsung Medical Center
Clinical Utility of VI-RADS in Diagnosis of MIBC	NCT05097404	Radical Cystect... Muscle-Invasive... Multiparametric... Vesical Imaging...	18 Years -	Samsung Medical Center
Clinical Utility of VI-RADS in Diagnosis of MIBC	NCT05097404	Radical Cystect... Muscle-Invasive... Multiparametric... Vesical Imaging...	18 Years -	Samsung Medical Center
Clinical Utility of VI-RADS in Diagnosis of MIBC	NCT05097404	Radical Cystect... Muscle-Invasive... Multiparametric... Vesical Imaging...	18 Years -	Samsung Medical Center

Spots Global Cancer Trial Database for vesical imaging report and data system